/2561 November 12, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q3/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited

. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public

/2561 June 19, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q1/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited

/2561 August 7, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q2/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited

Acquisition of Assets of DOD Biotech Public Company Limited regarding the Acquisition of Land and Establishment of Subsidiary, which is Class 2 Transaction (Schedule 1) DOD Biotech Public Company Limited ( the

our aspiration to become “Customers’ Life Platform of Choice”, meaning the most-preferred platform that can meet customers’ needs in every aspect of their lives, in order to deliver an excellent

Community (AEC), and the advancing digital age amid the rapid pace of technological advancement, thus leading to changing customer behavior, regulatory changes and life platform-driven competition. Given the

over the long term. Guided by our core strategies of “Customer Centricity", KBank has decided to redefine our aspiration to become “Customers’ Life Platform of Choice”, meaning the most-preferred

(DTF), a leading global producer of Biaxially-oriented Polyeth- ylene Terephthalate (BOPET) and Polyethylene Naphthalate (PEN) films with total film capacity of 180kt per annum. This acquisition includes

delivering an excellent customer experience in order to empower every customer’s life and business, we prioritize the offering of attentive and inclusive services as a trustworthy service provider. We can